Processa Pharmaceuticals, Inc. Net Change in Cash
Processa Pharmaceuticals, Inc. (PCSA) reported Net Change in Cash of -$5.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$3.85M, a 325.47% decline year-over-year.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $1.71M, a 59.52% decline year-over-year.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $4.21M, a 0.56% decline year-over-year.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $4.24M.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $4.35M.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$3.51M.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$1.80M.
- Processa Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$9.99M, a 1024.21% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.34M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$3.85M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $4.35M 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $5.12M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $5.75M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $1.71M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$3.51M 10-K · filed 2026-03-18 | |||
| 2024-09-30 | -$1.81M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $864.92K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $4.21M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$1.80M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $357.08K 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $2.17M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $4.24M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$9.99M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$7.44M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$4.43M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$2.10M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $1.08M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $3.68M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $5.41M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $7.63M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $14.72M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | -$366.11K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$238.88K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$549.26K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$1.05M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$1.24M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$1.02M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | -$492.43K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | -$1.11M 10-K · filed 2020-03-06 | |||
| 2018-09-30 | -$423.21K 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $3.02K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |